(Cincinnati, OH; May 22, 2012) – Camargo Pharmaceutical Services, an end-to-end drug development service provider specializing in the 505(b)(2) process, has appointed K. Gary Barnette as Vice President of drug development, a key appointment as the company continues to expand. He will be stationed in the Durham, N.C., office.
An accomplished leader, Barnette is responsible for the growth of the company and excellent customer service utilizing his experience within the drug development industry and his knowledge of Food and Drug Administration (FDA) regulations.
Barnette’s leadership experience encompasses the past 15 years, most recently as the Vice President of Clinical Research and Development strategy at GTx Inc. in Memphis, Tenn. His responsibilities included development of the clinical strategy of all clinical programs and the scientific design and authorship of all clinical protocols and other clinical documents including Institutional Review Boards and Ethics Committees.
During his tenure at GTx, Barnette was a member of Joint Drug Development Committees with industry leaders Merck, Orion, Johnson & Johnson and Ipsen. The goals of these Joint Committees were to develop clinical and regulatory strategy and implement corporate goals in the drug development of various products.
Prior to his position at GTx, Barnette served as the Director of Regulatory Affairs for Solvay Pharmaceuticals in Marietta, Ga., and for the FDA office of Clinical Pharmacology and Biopharmaceutics as a reviewer of more than 50 NDA and sNDA submissions and more than 200 IND submissions.
“We are delighted to have Gary working on our team,” stated Ken Phelps, Camargo President and CEO. “His extensive experience within regulatory affairs is important as Camargo looks toward the future growth of the company.”
A published professional, Barnette’s work has been featured in the Journal of Cachexia, Sarcopenia and Muscle, Journal of Urology and Journal of Clinical Oncology.
About Camargo Pharmaceutical Services
Camargo Pharmaceutical Services is an end-to-end drug development service provider specializing in the 505(b)(2) approval pathway. Camargo works with companies to develop comprehensive programs, managing every facet of the plan from formulating and testing the drug product, to conducting clinical studies and FDA application submissions. Connect with Camargo on LinkedIn, the President’s blog or visit www.camargopharma.com for more information.
